Xinguo Jiang

Xinguo Jiang

Auto-generated profile, based on publicly available information

Xinguo Jiang

VA Palo Alto Health Care System

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
XJXinguo Jiang
Xinguo Jiang
DSDavid J. Shapiro
David J. Shapiro

10 May 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
WTWen Tian
Wen Tian
SRStanley Glenn Rockson
Stanley Glenn Rockson
XJXinguo Jiang
Xinguo Jiang
JKJeanna Kim
Jeanna Kim
ABAdrian Begaye
Adrian Begaye
MNMark R Nicolls
Mark R Nicolls
Lymphedema is a common debilitating condition with very limited treatment options, and leukotriene B4may be a key pathogenic molecule and therapeutic target.

18 October 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
SRStanley Glenn Rockson
Stanley Glenn Rockson
WTWen Tian
Wen Tian
XJXinguo Jiang
Xinguo Jiang
TKTatiana Kuznetsova
Tatiana Kuznetsova
FHFrancois Haddad
Francois Haddad
MNMark R Nicolls
Mark R Nicolls
BACKGROUND. Lymphedema is a common condition affecting millions around the world that still lacks approved medical therapy. Because ketoprofen, an NSAID, has been therapeutic in experimental lymphedema, we evaluated its efficacy in humans. METHODS. We first performed an exploratory open-label trial. Patients with either primary or secondary lymphedema received ketoprofen 75 mg by mouth 3 times daily for 4 months. Subjects were evaluated for changes in histopathology, with skin thickness, limb volume, and tissue bioimpedance changes serving as secondary endpoints. Based on our encouraging findings, we next conducted a placebo-controlled trial, with the primary outcome defined as a change in skin thickness, as measured by skin calipers. Secondary endpoints for this second study included histopathology, limb volume, bioimpedance, and systemic inflammatory mediators. RESULTS. We enrolled 21 lymphedema patients in the open-label trial, from November 2010 to July 2011. Histopathology and skin thickness were significantly improved at 4 months compared with baseline. In the follow-up, double-blind, placebo-controlled trial, we enrolled 34 patients from August 2011 to October 2015, with 16 ketoprofen recipients and 18 placebo-treated subjects. No serious adverse events occurred. The ketoprofen recipients demonstrated reduced skin thickness, as well as improved composite measures of histopathology and decreased plasma granulocyte CSF (G-CSF) expression. CONCLUSION. These 2 exploratory studies together support the utility of targeted antiinflammatory therapy with ketoprofen in patients with lymphedema. Our results highlight the promise of such approaches to help restore a failing lymphatic circulation. TRIAL REGISTRATION. ClinicalTrials.gov NCT02257970.

14 November 2019 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
XJXinguo Jiang
Xinguo Jiang
WTWen Tian
Wen Tian
MNMark R. Nicolls
Mark R. Nicolls
SRStanley Glenn Rockson
Stanley Glenn Rockson
Obesity, insulin resistance, dyslipidemia, and hypertension are fundamental clinical manifestations of the metabolic syndrome. Studies over the last few decades have implicated chronic inflammation and microvascular remodeling in the development of obesity and insulin resistance. Newer observations, however, suggest that dysregulation of the lymphatic system underlies the development of the metabolic syndrome. This review summarizes recent advances in the field, discussing how lymphatic abnormality promotes obesity and insulin resistance, and, conversely, how the metabolic syndrome impairs lymphatic function. We also discuss lymphatic biology in metabolically dysregulated diseases, including type 2 diabetes, atherosclerosis, and myocardial infarction.

1 June 2014 in Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
XJXinguo Jiang
Xinguo Jiang
YSYon K. Sung
Yon K. Sung
WTWen Tian
Wen Tian
JQJin Qian
Jin Qian
GSGregg L. Semenza
Gregg L. Semenza
MNMark R Nicolls
Mark R Nicolls
Alloimmune inflammation damages the microvasculature of solid organ transplants during acute rejection. Although immunosuppressive drugs diminish the inflammatory response, they do not directly promote vascular repair. Repetitive microvascular injury with insufficient regeneration results in prolonged tissue hypoxia and fibrotic remodeling. While clinical studies show that a loss of the microvascular circulation precedes and may act as an initiating factor for the development of chronic rejection, preclinical studies demonstrate that improved microvascular perfusion during acute rejection delays and attenuates tissue fibrosis. Therefore, preservation of a functional microvasculature may represent an effective therapeutic strategy for preventing chronic rejection. Here, we review recent advances in our understanding of the role of the microvasculature in the long-term survival of transplanted solid organs. We also highlight microvessel-centered therapeutic strategies for prolonging the survival of solid organ transplants.

19 January 2024 in EMBO Reports
Verified
Journal Article
Open access
HKHyunbum Kim
Hyunbum Kim
YLYu Liu
Yu Liu
JKJiwon Kim
Jiwon Kim
YKYunhye Kim
Yunhye Kim
TKTimothy Klouda
Timothy Klouda
KYKe Yuan
Ke Yuan
Vascular remodeling is the process of structural alteration and cell rearrangement of blood vessels in response to injury and is the cause of many of the world’s most afflicted cardiovascular conditions, including pulmonary arterial hypertension (PAH). Many studies have focused on the effects of vascular endothelial cells and smooth muscle cells (SMCs) during vascular remodeling, but pericytes, an indispensable cell population residing largely in capillaries, are ignored in this maladaptive process. Here, we report that hypoxia-inducible factor 2α (HIF2α) expression is increased in the lung tissues of PAH patients, and HIF2α overexpressed pericytes result in greater contractility and an impaired endothelial-pericyte interaction. Using single-cell RNAseq and hypoxia-induced pulmonary hypertension (PH) models, we show that HIF2α is a major molecular regulator for the transformation of pericytes into SMC-like cells. Pericyte-selective HIF2α overexpression in mice exacerbates PH and right ventricular hypertrophy. Temporal cellular lineage tracing shows that HIF2α overexpressing reporter NG2+ cells (pericyte-selective) relocate from capillaries to arterioles and co-express SMA. This novel insight into the crucial role of NG2+ pericytes in pulmonary vascular remodeling via HIF2α signaling suggests a potential drug target for PH.